Walk through a premium clinic in Seoul's Gangnam district and you'll see something UK practitioners are only beginning to adopt: a treatment menu built around regenerative injectables rather than fillers.
The two categories leading this shift are polynucleotides and exosomes — and both are heading for the UK.
Polynucleotides
Polynucleotide injectables, derived from purified salmon DNA, are designed to stimulate tissue repair and fibroblast activity rather than simply filling space. In Seoul they're used for under-eye rejuvenation, skin tightening and scalp protocols.
Products like Nucleofill and Re:Polynucleotide have built loyal followings because they address the one thing fillers can't: the biological quality of the skin itself. Patients see improved texture, tone and elasticity over a course of sessions.
Exosomes
Exosomes — cell-derived signalling particles — are the more experimental end of the frontier. In Korea they're being used topically after microneedling and, in some clinics, as injectables, with claims around regeneration and pigmentation.
The regulatory picture for exosomes is still evolving, and UK practitioners should treat marketing claims with appropriate caution. But the direction of travel — toward treatments that signal the skin to repair itself — is unmistakable.
What UK practitioners should watch
- Polynucleotides are the more immediately adoptable category, with authorised product available in the UK
- Patient education matters: regenerative results build over weeks, not minutes
- Course-based pricing suits these protocols — patients commit to a series
Revive Pharma stocks authorised polynucleotide ranges for UK wholesale. Expect this category to grow fast as patients seek out the 'glass skin' results they associate with Korean practice.
